Gary Peters

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Steen Husted, Håkan Emanuelsson, Stan Heptinstall et al. · European Heart Journal · 2006 · 740 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Christopher P. Cannon, Steen Husted, Robert A. Harrington et al. · Journal of the American College of Cardiology · 2007 · 495 citations

Medicine, Cardiology, Pharmacology +12

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

Robert F. Storey, Steen Husted, Robert A. Harrington et al. · Journal of the American College of Cardiology · 2007 · 486 citations

Medicine, Pharmacology, Pharmacotherapy +16

Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement

Charles W. Francis, Scott D. Berkowitz, Philip C. Comp et al. · New England Journal of Medicine · 2003 · 319 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +13

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty

Charles W. Francis, Bruce L. Davidson, Scott D. Berkowitz et al. · Annals of Internal Medicine · 2002 · 210 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15